Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07104091 mass balance and bioavailability study in healthy volunteers
NCT07127770Phase 1Completed
- Sponsor
- Pfizer
- Start
- Aug 2025
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tegtociclib, sponsored by Pfizer. Primary endpoints: Percentage of Total Radiocarbon (14C) excreted in urine at 14 days, Percentage of Total Radiocarbon (14C) excreted in feces at 14 days and 5 more. Started Aug 2025; status: completed.
02
Drugs
tegtociclib
Beyond the preview
Go deeper on NCT07127770.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07127770.